Targeted Therapies in Oncology
October 1, 2022
October 2, 2022
Volume: 11
Issue: 14
September 2022
Volume: 11
Issue: 12
August 2022
Volume: 11
Issue: 11
July 1, 2022
Volume: 11
Issue: 9
July 2, 2022
Volume: 11
Issue: 10
June 1, 2022
Volume: 11
Issue: 8
May 2022
Volume: 11
Issue: 7
April 2, 2022
Volume: 6
April 1, 2022
Volume: 11
Issue: 5
March 2022
Volume: 11
Issue: 4
February 2, 2022
Volume: 11
Issue: 3
February 1, 2022
Volume: 11
Issue: 2
January 2022
Volume: 11
Issue: 1
December 1, 2021
Volume: 10
Issue: 7
December 2, 2021
Volume: 10
Issue: 18
November 1, 2021
Volume: 1
Issue: 1
October 2, 2021
Volume: 10
Issue: 14
October 1, 2021
Volume: 10
Issue: 13
September 2021
Volume: 10
Issue: 12
August 2021
Volume: 10
Issue: 11
July 1 2021
Volume: 10
Issue: 9
July 2 2021
Volume: 10
Issue: 10
June 2021
Volume: 10
Issue: 8
May 2021
Volume: 10
Issue: 7
April 2, 2021
Volume: 10
Issue: 6
April 1, 2021
Volume: 10
Issue: 5
March 2021
February 2, 2021
Volume: 10
Issue: 3
February 1, 2021
Volume: 10
Issue: 2
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5